In 2013 Intel, Imec, the five Flemish universities (UA, UGent, KU Leuven, Universiteit Hasselt, VU Brussel) and Janssen founded the ExaScience Life Lab at the Imec campus in Leuven, a unique initiative in our country. In this lab Intel's supercomputing expertise is combined with Flanders' extensive expertise in life sciences and biotechnology. This collaboration will lead to new solutions for supercomputers and breakthroughs in the areas of life sciences and biotechnology. 

High-performance Computing leads to new insights and breakthroughs in the areas of life sciences and biotechnology. The use of supercomputers will play a strategic role in laboratory analyses in the future. The traditional method consists of endless experiments with variations of existing molecules, until a variant is found which could indeed be more efficient. There is no need to tell how time-consuming and costly this procedure is. The alternative would be a computer calculating the properties of these potential variants. However, to do this we need good digital models of complex molecules and their behavior. Supercomputers are needed to make it possible to predict complex chemical reactions to make the search for new treatments more efficient.

A long-term collaboration with companies and knowledge institutions with additional expertise is a necessity for Janssen to be able to continue to fully utilize its knowledge and know-how and create added value for the patient. Potential synergies in this area must be quickly identified and developed.

A long-term collaboration with companies and knowledge institutions with additional expertise is a necessity for Janssen to be able to continue to fully utilize its knowledge and know-how. 

Serious_gaming.jpg

Durabilité
Économique

Janssen believes that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. 

Janssen must constantly reinvent itself in order to cope with the structural and economic changes that affect its environment. This is why Janssen is committed to build partnerships within an open innovation model, and to the continuous alignment of its cost-competitiveness by only developing medicines with a high therapeutic added value. 

For Janssen this means specifically: being focused and a leader in research & development, and being efficient and progressive in terms of production with the aim of bringing new therapeutic solutions to patients quicker and at less expense, and implementing a growth strategy to ensure our continued investment in all these areas.